Morgan Stanley lowered the firm’s price target on BioNTech (BNTX) to $125 from $134 and keeps an Overweight rating on the shares. In conjunction with its Q4 report, BioNTech surprisingly announced a leadership transition, which overshadows the Q4 results and initial 2026 guidance, the analyst tells investors. However, following the selloff in the stock, the firm sees shares as undervalued ahead of a number of data read-outs, the analyst added.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BNTX:
- BioNTech price target lowered to $128 from $143 at BMO Capital
- BioNTech price target lowered to $130 from $145 at Citi
- Balancing Near-Term Headwinds and Strategic Transition: Why a Hold Rating Remains Warranted
- BioNTech: Attractive Near-Cash Valuation with Robust Late-Stage Pipeline Offsetting Revenue Declines and Leadership Transition Risks
- Jefferies cuts BioNTech price target, says stock is cheap